# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Cardiff Oncology (NASDAQ:CRDF) reported quarterly losses of $(0.26) per share which missed the analyst consensus estimate of $(...
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Cardiff Oncology (NASDAQ:CRDF) with a Buy and maintains $14 pr...
Cardiff Oncology (NASDAQ:CRDF) reported quarterly losses of $(0.22) per share which beat the analyst consensus estimate of $(0....
– In RAS-mutated mCRC, novel preclinical finding demonstrates onvansertib inhibits the tumor's ability to adapt to hypoxia ...
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Cardiff Oncology (NASDAQ:CRDF) with a Buy and raises the price ...
U.S. stocks traded lower toward the end of trading, with the S&P 500 edging lower on Monday. The Dow traded down 0.20% to ...